Literature DB >> 8539646

Nuclear imaging of solid hepatic masses.

M F Kinnard1, A Alavi, R A Rubin, G R Lichtenstein.   

Abstract

This review has focused on the unique role of radionuclide scintigraphy in characterization of hepatic mass lesions. Radionuclide scintigraphy, unlike most other imaging modalities, is based on specific physiological and biochemical properties of each pathological entity that affects the liver. Hepatic scintigraphy, with its widespread availability, noninvasive nature, and relatively low cost is a powerful adjunct to other imaging techniques in the investigation of hepatic mass lesions. We have reviewed clinical presentation and characteristic findings of most hepatic lesions and have described reported findings with all available imaging modalities with particular emphasis on hepatic scintigraphy (Table 1) as well as a suggested algorithm for workup of solid hepatic masses (Fig 6). Additionally, the role of newer, more specialized techniques including PET scanning, 123I-labeled VIP, and 111In-labeled DTPA-D-Phe-octreotide scanning are reviewed. Hepatic nuclear scintigraphy continues to play an important role in the management of patients with solid hepatic masses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8539646     DOI: 10.1016/s0037-198x(05)80024-0

Source DB:  PubMed          Journal:  Semin Roentgenol        ISSN: 0037-198X            Impact factor:   0.800


  5 in total

1.  Benign Neoplasms of the Liver.

Authors:  Michael K. Porayko; Cuckoo Choudhary
Journal:  Curr Treat Options Gastroenterol       Date:  2001-12

Review 2.  Characteristics of common solid liver lesions and recommendations for diagnostic workup.

Authors:  Nimer Assy; Gattas Nasser; Agness Djibre; Zaza Beniashvili; Saad Elias; Jamal Zidan
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

3.  Diagnosis and management of hepatic focal nodular hyperplasia.

Authors:  A Venturi; F Piscaglia; G Vidili; S Flori; R Righini; R Golfieri; L Bolondi
Journal:  J Ultrasound       Date:  2007-08-01

4.  Care of cancer patients with liver and bone metastases - the place of pharmaceutical care in a balanced plan, focused on the patient's needs and goals.

Authors:  Katarzyna A Rygiel; Mariola Drozd; Lucyna Bułaś
Journal:  Arch Med Sci       Date:  2016-06-13       Impact factor: 3.318

Review 5.  Distinguishing benign from malignant liver tumours.

Authors:  Jay P Heiken
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.